Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Utility of Flow Cytometry (FC) in the Assessment of Therapeutic Efficacy in Myelodysplastic Syndromes (MDS) After Therapeutic Intervention.

Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Peter Gambell, BSc, MHSM, Neil Came, MBBS, FRACP, FRCPA, Kevin Lynch, MB, BS, FFPM, John F. Seymour, MBBS, PhD, FRACP, Miles Prince, MBBS, MD, MRACMA, FRACP, FRCPA, David A Westerman, MBBS, FRACP, FRCPA

Blood (2009) 114 (22): 2767.

https://doi.org/10.1182/blood.V114.22.2767.2767

Published: 2009

Journal Articles

Appropriate Limits for Microbial Contamination after PBSC Processing and the New European Pharmacopoeia Method for Microbiological Control of Cellular Products.

Dominic Wall, PhD, Peter Gambell, BSc, Alexander Yallouridis, BSc, Luiza Mints-Kotowska, BSc, Irene Lazzarini, BSc, Miles Prince, MBBS,MD,FRACP,FRCPA

Blood (2006) 108 (11): 3386.

https://doi.org/10.1182/blood.V108.11.3386.3386

Published: 2006

Journal Articles

Prolonged Hematologic Toxicity from the Hyper-CVAD Regimen; Manifestations, Frequency, and Natural History in a Cohort of 125 Consecutive Patients.

Saar Gill, MBBS, Steven Lane, MBBS, Julie Crawford, MBBS, Peter Mollee, MBBS, Paula Marlton, MBBS, Gavin Cull, MBBS, Miles Prince, MBBS, MD, John Francis Seymour, MBBS, PhD

Blood (2006) 108 (11): 2441.

https://doi.org/10.1182/blood.V108.11.2441.2441

Published: 2006

Journal Articles

Augmented Preparative Regimens Using Total Body Irradiation or BCNU Prior to Autologous Stem Cell Transplant (AuSCT) Are Well-Tolerated and Yield Substantial Rates of Progression-Free Survival in Patients with Poor Risk Hodgkin Lymphoma (HL) or Diffuse Large B-Cell Lymphoma (DLBCL).

David S. Ritchie, MBBS, PhD, FRACP, FRCPA, John F. Seymour, MBBS, FRACP, Sarah Thompson, RN, Michael McManus, MBBS, MD, MRCP, FRCR, Miles Prince, MBBS, MD, FRACP, FRCPA

Blood (2005) 106 (11): 5499.

https://doi.org/10.1182/blood.V106.11.5499.5499

Published: 2005

Journal Articles

In Vivo Tracking of Macrophage Activated Killer Cells to Sites of Metastatic Ovarian Carcinoma.

David S. Ritchie, MBBS, PhD, FRACP, FRCPA, Linda Mileshkin, MBBS, FRACP, Dominic M. Wall, PhD, Jacques Bartholyens, PhD, Mick Thompson, BSc, Rod Hicks, MBBS, MD, FRACP, Miles Prince, MBBS, MD, FRACP, FRCPA

Blood (2005) 106 (11): 3874.

https://doi.org/10.1182/blood.V106.11.3874.3874

Published: 2005

Journal Articles

Tracking Dendritic Cells In Vivo in Patients with Multiple Myeloma.

Dominic M. Wall, PhD, Mick Thompson, BSc, Linda Mileshkin, MBBS, FRACP, Bruce Loveland, PhD, Judi Coverdale, BSc, Pei-Xiang Xing, PhD, Jacques Bartholeyns, PhD, Rodney Hicksm, MBBS, MD, FRACP, Miles Prince, MBBS, MD, FRACP, FRCPA

Blood (2005) 106 (11): 3469.

https://doi.org/10.1182/blood.V106.11.3469.3469

Published: 2005

Journal Articles

Prolonged Severe Pancytopenia and Myelodysplastic Features Following Alemtuzumab Therapy in Patients with Cutaneous T-Cell Lymphomas.

Simon D. Gibbs, MBBS, David Alan Westerman, MBBS, John Francis Seymour, MBBS, Miles Prince, MBBS, MD

Blood (2004) 104 (11): 2645.

https://doi.org/10.1182/blood.V104.11.2645.2645

Published: 2004

NARROW

Utility of Flow Cytometry (FC) in the Assessment of Therapeutic Efficacy in Myelodysplastic Syndromes (MDS) After Therapeutic Intervention.

Appropriate Limits for Microbial Contamination after PBSC Processing and the New European Pharmacopoeia Method for Microbiological Control of Cellular Products.

Prolonged Hematologic Toxicity from the Hyper-CVAD Regimen; Manifestations, Frequency, and Natural History in a Cohort of 125 Consecutive Patients.

Augmented Preparative Regimens Using Total Body Irradiation or BCNU Prior to Autologous Stem Cell Transplant (AuSCT) Are Well-Tolerated and Yield Substantial Rates of Progression-Free Survival in Patients with Poor Risk Hodgkin Lymphoma (HL) or Diffuse Large B-Cell Lymphoma (DLBCL).

In Vivo Tracking of Macrophage Activated Killer Cells to Sites of Metastatic Ovarian Carcinoma.

Tracking Dendritic Cells In Vivo in Patients with Multiple Myeloma.

Prolonged Severe Pancytopenia and Myelodysplastic Features Following Alemtuzumab Therapy in Patients with Cutaneous T-Cell Lymphomas.

Email alerts

ASH Publications

American Society of Hematology

Utility of Flow Cytometry (FC) in the Assessment of Therapeutic Efficacy in Myelodysplastic Syndromes (MDS) After Therapeutic Intervention.

Appropriate Limits for Microbial Contamination after PBSC Processing and the New European Pharmacopoeia Method for Microbiological Control of Cellular Products.

Prolonged Hematologic Toxicity from the Hyper-CVAD Regimen; Manifestations, Frequency, and Natural History in a Cohort of 125 Consecutive Patients.

Augmented Preparative Regimens Using Total Body Irradiation or BCNU Prior to Autologous Stem Cell Transplant (AuSCT) Are Well-Tolerated and Yield Substantial Rates of Progression-Free Survival in Patients with Poor Risk Hodgkin Lymphoma (HL) or Diffuse Large B-Cell Lymphoma (DLBCL).

In Vivo Tracking of Macrophage Activated Killer Cells to Sites of Metastatic Ovarian Carcinoma.

Tracking Dendritic Cells In Vivo in Patients with Multiple Myeloma.

Prolonged Severe Pancytopenia and Myelodysplastic Features Following Alemtuzumab Therapy in Patients with Cutaneous T-Cell Lymphomas.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only